Prescribing information

 

Downloadable resources for you and your patients.

These resources are designed for you and your patients

Materials for healthcare professionals to provide you with more in-depth information about MAYZENT.

Materials for patients are designed to help them manage their symptoms, better understand their disease and improve doctor–patient communication.

Risk management materials

Image of the Prescriber's checklist

PRESCRIBER'S CHECKLIST

A checklist of important points to remember before, during and after treatment with MAYZENT.

This material is part of MAYZENT Educational Risk Minimisation Materials. 

View

This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.

 

Summary of product characteristics for Mayzent

SUMMARY OF PRODUCT CHARACTERISTICS FOR MAYZENT

Summary of product characteristics for MAYZENT.

This material is part of MAYZENT Educational Risk Minimisation Materials.

View  Download

This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.

 

Image of the Patient and Caregiver Guide booklet.

MAYZENT PATIENT AND CAREGIVER GUIDE

A guide detailing important information about MAYZENT for patients and caregivers.

This material is part of MAYZENT Educational Risk Minimisation Materials.

View

This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.

 

Image of the Pregnancy card.

MAYZENT PREGNANCY CARD

A card detailing information for female patients of childbearing potential.

This material is part of MAYZENT Educational Risk Minimisation Materials.

View

This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.

 

 

Mayzent patient materials

Image of the Young person's guide to Gilenya patient booklet.

INTRODUCTION TO MAYZENT

Patient resource to explain how Mayzent works and how Mayzent can help SPMS patients with active disease.

Preview

 

Image of the Young person's guide to Gilenya patient booklet.

BEFORE YOU START MAYZENT

Patient resource to provide details around pre-initiation requirement with Mayzent for SPMS patients with active disease.

Preview

 

Image of the Young person's guide to Gilenya patient booklet.

STARTING TREATMENT WITH MAYZENT

Patient resource to provide details around treatment initiation requirements and process with Mayzent for SPMS patients with active disease.

Preview

 

Image of the Young person's guide to Gilenya patient booklet.

CONTINUING TREATMENT WITH MAYZENT

Patient resource to provide details around ongoing monitoring and adherence requirements while on Mayzent.

Preview

Indication: MAYZENT is indicated for the treatment of adult patients with SPMS with active disease evidenced by relapses or imaging features of inflammatory activity.1

SPMS, secondary progressive multiple sclerosis.

Reference

  1. MAYZENT (siponimod) Summary of Product Characteristics.
     
SIP20-C001f May 2020.
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at http://www.report.novartis.com/
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]